ALZN

Alzamend Neuro Inc

NASDAQ: ALZN · HEALTHCARE · BIOTECHNOLOGY

$1.34

+2.29% today

Updated 2026-07-29

Market cap

$5.14M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.75

Dividend yield

—

52W range

$1 – $3

Volume

0.2M

Market cap

$5.14M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.75

Dividend yield

—

52W range

$1 – $3

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$25.00

+1765.67%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-2.80M

Key financials

Revenue Net Income Free Cash Flow

Metric	2023	2024	2025	2026	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-14.88M	$-9.95M	$-4.51M	$-8.77M	$-2.87M
EPS	—	—	—	—	$-3.75
Free cash flow	$-8.92M	$-8.42M	$-6.87M	$-8.07M	$-2.80M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ALZN	$5.14M	21	4.3	3.0	5.0	4.0	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

Alzamend Neuro Inc trades at $1.34. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score.

Frequently asked questions

What is Alzamend Neuro Inc's stock price?

Alzamend Neuro Inc (ALZN) trades at $1.34.

Is Alzamend Neuro Inc overvalued?

Alzamend Neuro Inc carries a Smart Value Score of 21/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Alzamend Neuro Inc (ALZN)?

The 12-month analyst consensus target is $25.00, about 1765.7% above the current $1.34. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-322.36%

Beta0.14

50D MA$1.17

200D MA$1.74

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ALZN vs LLY →ALZN vs JNJ →ALZN vs ABBV →Stock screener →